Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours

J Stockley, R Akhand, A Kennedy, C Nyberg, E J Crosbie, R J Edmondson, J Stockley, R Akhand, A Kennedy, C Nyberg, E J Crosbie, R J Edmondson

Abstract

Background: MCM5 is a protein involved in DNA replication, facilitating cell proliferation. In normal epithelium MCM5 expression is restricted to the cells in the basal proliferative compartments, however in the presence of a tumour MCM5 positive cells are present at the surface epithelium and are shed into bodily fluids. The aim of this study was to determine the sensitivity of MCM5 as a biomarker for the detection of endometrial and ovarian cancer.

Methods: Patients with known ovarian or endometrial cancers, or known benign gynaecological conditions, were enrolled. Informed consent was obtained prior to the collection of full void urine, and either a vaginal tampon (worn for 6-8 h), or a vaginal swab. Vaginal secretions were extracted from the tampon or swab, centrifuged and lysed. Urine samples were centrifuged and lysed. MCM5 levels were determined by MCM5-ELISA (Arquer Diagnostics Ltd).

Results: 125 patients completed the study protocol, 41 patients had endometrial cancer, 26 ovarian cancer, and 58 benign controls. All patients provided a urine sample and either a tampon or vaginal swab sample. Urine MCM5 levels were higher in cancer patients than controls (p < 0.0001), there was no significant difference in levels between tampon samples or vaginal swab samples in cancer patients when compared to controls. Performance of MCM5 to discriminate cancer from benign disease was high with an area under the ROC curve of 0.83 for endometrial cancer and 0.68 for ovarian cancer. Using a cut off of 12 pg/mL, overall sensitivity for endometrial cancer was 87.8, and 61.5% for ovarian cancer with a specificity of 75.9%.

Conclusions: MCM5 is a novel sensitive and specific biomarker for the detection of ovarian and endometrial tumours in urine samples, which is likely to have clinical utility as a diagnostic aid.

Keywords: Biomarker; Early detection; Endometrial cancer; MCM5; Ovarian cancer.

Conflict of interest statement

RA and EJC declare that they have no competing interests. RJE has received consultancy fees from Arquer Diagnostics. JS, AK and CN are employees of Arquer Diagnostics, holding share options.

Figures

Fig. 1
Fig. 1
MCM5 level in Benign vs Cancer patients detected in (a) Urine, (b) Vaginal Tampon, (c) Vaginal Swab
Fig. 2
Fig. 2
MCM5 levels in urine sediment in Benign vs Endometrial Cancer
Fig. 3
Fig. 3
MCM5 levels in urine sediment in Benign vs Ovarian Cancer
Fig. 4
Fig. 4
Receiver Operator Curve showing performance of MCM5 as a diagnostic test for (a) Endometrial Cancer and (b) Ovarian Cancer

References

    1. Lheureux S, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi: 10.1016/S0140-6736(18)32552-2.
    1. Morice P, et al. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi: 10.1016/S0140-6736(15)00130-0.
    1. Jacobs IJ, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–956. doi: 10.1016/S0140-6736(15)01224-6.
    1. Kinde I, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.
    1. Fiegl H, et al. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomark Prev. 2004;13(5):882–888.
    1. Bakkum-Gamez JN, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015;137(1):14–22. doi: 10.1016/j.ygyno.2015.01.552.
    1. Dudderidge T, et al. A novel, non-invasive test enabling bladder Cancer detection in urine sediment of patients presenting with Haematuria-a prospective multicentre performance evaluation of ADXBLADDER. Br J Cancer. 2010;103(5):701-7.
    1. Dudderidge TJ, et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 2010;103(5):701–707. doi: 10.1038/sj.bjc.6605785.
    1. Murphy N, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58(5):525–534. doi: 10.1136/jcp.2004.018895.
    1. Snyder M, He W, Zhang JJ. The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation. Proc Natl Acad Sci U S A. 2005;102(41):14539–14544. doi: 10.1073/pnas.0507479102.
    1. Bossuyt PM, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Bmj. 2015;351:h5527. doi: 10.1136/bmj.h5527.
    1. Pepe MS, et al. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem. 2016;62(5):737–742. doi: 10.1373/clinchem.2015.252163.
    1. Cancer_Research_UK. . 2020 [cited 2020 Jan].
    1. NICE, Suspected cancer:recognition and referral. NICE guidance [NG12] Published June 2015. . Accessed 20 Sept.
    1. Skates SJ, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12(12):5383–5394. doi: 10.1021/pr400132j.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel